Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo principio activo (difluorobencil etalonaminas) con actividad antimicrobiana

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20140908003
Publicado:
16/09/2015
Caducidad:
15/09/2016
Resumen:
Una universidad española ha sintetizado a nivel de laboratorio nuevos compuestos (difluorobencil etalonaminas) con actividad antimicrobiana probada, especialmente contra las especies de Mycobacterium y Nocardia. Como resultado, estos compuestos podrían ser de utilidad en el sector farmacéutico como principio activo para el tratamiento de enfermedades infecciosas causadas por estos microorganismos. La universidad, que ha solicitado la patente, busca compañías farmacéuticas con el fin de licenciar la invención y establecer acuerdos de colaboración técnica.

Details

Tittle:
New active ingredient (difluorobenzyl ethalonamines) with antimicrobial activity
Summary:
A Spanish university has synthesised (at laboratory level) new compounds (difluorobenzyl ethanolamines) with proved antimicrobial activity, especially against Mycobacterium and Nocardia species. As a result, these compounds would be useful in the pharmaceutical sector as an active ingredient for the treatment of infectious diseases caused by these microorganisms. A Spanish patent has been granted. Pharmaceuticals industries are sought for licensing the invention or for technical collaborations.
Description:
Pathogenic bacterial species of the genus Mycobacterium and Nocardia are the causative agent of diseases as tuberculosis, leprosy and other pulmonary, cutaneous or central nervous system infections. Specifically, Mycobacterium tuberculosis (TB) causes human tuberculosis and is responsible of almost two million deaths every year, being also one of the opportunistic pathogen with more incidence on HIV+ (human immunodeficiency virus) patients. Nowadays, a variety of active compounds against TB are available, as isoniazid and pyrazinamide, that affect the bacteria´s synthesis of fatty acids, and ethambutol, implied in the biosynthesis of the bacteria´s cell wall. However, it is considered a priority to find and develop new medicines which shorten the current treatments and solve resistance problems of the drugs in use.

Spanish Researchers have synthesized new compounds that show growth inhibitory activity over Mycobacterium and Nocardia species. The obtained new compounds belong to the family of fluorinated ethanolamines (specifically, difluorobenzyl ethanolamines) and have demonstrated selective antimicrobial activity in vitro against the aforementioned microorganisms. This selectivity suggests a specific mechanism of action on special characteristics of these species. Furthermore, synthesized molecules show similar or lower minimal inhibitory concentration (MIC) than a frontline antitubercular agent such as ethambutol, currently used to treat different types of tuberculosis.

The main application of the technology is in the pharmaceutical area, as active ingredient for the treatment of infectious diseases caused by Mycobacterium and Nocardia.
Advantages and Innovations:
The most remarkable advantages provided by this technology are:
- Selectivity of the compounds against species of the genera Mycobacterium and Nocardia.
- High in vitro antimicrobial activity, with MIC values similar or lower than those for therapeutic agents in use as ethambutol.
- Improvement of pharmacodynamic properties of the potentially active compounds due to the stability provided by the difluorobenzyl group.
- Less synthetic steps than existing procedures to obtain the four possible diastereoisomers of the molecules.
Stage of Development:
Under development/lab tested
IPs:
Granted patent or patent application essential
CommeR Statunts Regarding IPR Status:
Spanish patent granted

Partner sought

Type and Role of Partner Sought:
Enterprise in the specific area of pharmaceuticals for infectious diseases, for licensing the invention, testing of applications, adaptation to specific needs, production and marketing.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos